SCHEMBL5250449

SCHEMBL5250449

O=S(=O)(c1ccc(Cl)cc1)N1CCN(c2ccncc2)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.64
TP53 P04637 1/20 0.62
LSS P48449 2/20 0.60
KDM4E B2RXH2 1/20 0.59
LMNA P02545 1/20 0.59
HSD17B10 Q99714 1/20 0.59
ATM Q13315 1/20 0.58
CYP3A4 P08684 2/20 0.57
CYP2C9 P11712 2/20 0.57
CYP1A2 P05177 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C19 P33261 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
HIF1A Q16665 1/20 0.57
KMT2A Q03164 4/20 0.56
MEN1 O00255 3/20 0.56
F10 P00742 1/20 0.56
MAPK1 P28482 1/20 0.56
L3MBTL1 Q9Y468 2/20 0.55
MAPT P10636 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7549029 0.91 L3MBTL1 (0.67) HSD11B1TP53LSSLMNASMN1; SMN2
SCHEMBL5250380 0.89 HSD11B1 (0.78) HSD11B1LSSKDM4ELMNAHSD17B10
SCHEMBL7956164 0.85 LSS (0.70) LSSKDM4ELMNACYP3A4CYP2C9
SCHEMBL2963235 0.84 ALDH1A1 (0.72) HSD11B1LSSLMNAATMCYP3A4
SCHEMBL5327436 0.83 HSD11B1 (0.65) HSD11B1LSSKDM4ELMNAHSD17B10
SCHEMBL5250329 0.82 MEN1 (0.85) HSD11B1LSSLMNAATMSMN1; SMN2
SCHEMBL5251036 0.82 MAPT (0.75) HSD11B1LSSLMNAHSD17B10ATM
SCHEMBL10355428 0.82 ATM (0.81) LMNAATMSMN1; SMN2KMT2AMEN1
SCHEMBL4580893 0.82 ATM (0.81) LMNAATMSMN1; SMN2KMT2AMEN1
SCHEMBL7956653 0.81 GAA (0.67) HSD11B1LSSLMNACYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758884-A2 N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE Elan Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
US-20060035884-A1 N-cyclic sulfonamido inhibitors of gamma secretase ELAN PHARMACEUTICALS, INC. (US) 2006-02-16 US claimed
WO-2005113542-A2 N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE ELAN PHARMACEUTICALS, INC. (US) 2005-12-01 WO claimed
US-20060035884-A1 N-cyclic sulfonamido inhibitors of gamma secretase ELAN PHARMACEUTICALS, INC. (US) 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035884-A1 N-cyclic sulfonamido inhibitors of gamma secretase BACE1, BACE2, APH1B HSD11B1 1013/4885TP53 2283/4885LSS 518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.